Cypress will also get an additional $37.5 million in potential milestone-related payments associated with the development of Proprius’s therapeutic candidates.
The acquisition brings together Cypress’s drug development expertise, commercial resources and lead pharmaceutical candidate, milnacipran, which is currently under FDA review for the treatment of fibromyalgia, and Proprius’s unique portfolio of proprietary, high-value personalized medicine laboratory services and therapeutic product candidates.